Table 1 Characteristics and clinicopathological parameters of the recruited advanced oropharyngeal cancer patients
From: A predictive model for advanced oropharyngeal cancer patients treated with chemoradiation
|  | N (%) or mean ± SD (range) or median (range, IQR) |
|---|---|
Age (years) | 61.7 ± 9.9(36–93) |
Gender (Male/Female) | 139(95%)/8(5%) |
T classification (T1 + 2/ T3 + 4) | 50(33%)/97(67%) |
N classification (N0/N1/N2/N3) | 12(8%)/26(18%)/92(63%)/17(11%) |
Stage (III/ IVa/ IVb) | 19(13%)/96(65%)/32(22%) |
Body Height (cm) | 166.7 ± 6.1(152–185) |
Body Weight (kg) | 64.4 ± 12.4(36–100) |
BMI (kg/m2) | 23.2 ± 4.1(12.5–35.4) |
Tumor side (Right/Left) | 62(42%)/85(58%) |
Disease subsite (Tonsil/ Soft palate/ Tongue base/ Pharyngeal wall) | 94(64%)/12(8%)/14(10%)/27(18%) |
Previous treated cancer | 13(9%) |
  Oral cancer | 7 |
  Esophageal cancer | 3 |
  Hypopharyngeal cancer | 1 |
  Hepatocellular carcinoma | 1 |
  Rectal cancer | 1 |
Syn- or Meta-chronous cancer | 21(14%) |
  Esophageal cancer | 10 |
  Oral cancer | 4 |
  Lung cancer | 2 |
  Hepatocellular carcinoma | 1 |
  Oral and hypopharyngeal cancer | 1 |
  Hypopharyngeal cancer | 1 |
  Breast cancer | 1 |
  Thyroid cancer | 1 |
Differentiation (Well/Moderately/Poorly/Missing) | 3(2%)/37(25%)/37(25%)/70(48%) |
HPV (p16) (Positive/Negative/Missing) | 29(20%)/39(26%)/79(54%) |
Smoking habit (No/Yes) | 33(22%)/114(78%) |
Hemoglobulin (gm/dl) | 13.0 ± 2.2(4.1–16.5) |
Lymphocyte count (103/μl) | 1.6 ± 0.8(0.5–6.4) |
Monocyte count (102/μl) | 0.6 ± 0.4(0.2–4.1) |
Platelet count (103/μl) | 254.2 ± 85.4(91.0–475.0) |
Neutrophil count (103/μl) | 6.0 ± 2.8(1.2–17.2) |
LMR | 3.2 ± 1.8(0.5–8.9) |
PLR | 184.3 ± 102.0(36.7–697.2) |
NLR | 4.5 ± 2.9(0.9–16.2) |
SIRI | 264.3 ± 225.3(21.8–1391.4) |
SII | 1158.2 ± 935.5(133.0–5209.9) |
Median follow-up (range, IQR) (days) | 599(315–1446, 1131) |
Death within 1 year | 43(29%) |
Disease Persistence | 51(35%) |
Recurrence | 40(27%) |
 Local | 16 |
 Regional | 7 |
 Locoregional | 1 |
 Distant | 20 |